Journal of Genetic Counseling

, Volume 23, Issue 4, pp 594–603

Points to Consider in the Clinical Use of NGS Panels for Mitochondrial Disease: An Analysis of Gene Inclusion and Consent Forms

Next Generation Genetic Counseling

DOI: 10.1007/s10897-013-9683-2

Cite this article as:
Platt, J., Cox, R. & Enns, G.M. J Genet Counsel (2014) 23: 594. doi:10.1007/s10897-013-9683-2

Abstract

Mitochondrial next generation sequencing (NGS) panels offer single-step analysis of the numerous nuclear genes involved in the structure, function, and maintenance of mitochondria. However, the complexities of mitochondrial biology and genetics raise points for consideration in clinical use of these tests. To understand the current status of mitochondrial genetic testing, we assessed the gene offerings and consent forms of mitochondrial NGS panels available from seven US-based clinical laboratories. The NGS panels varied markedly in number of genes (101–1204 genes), and the proportion of genes causing “classic” mitochondrial diseases and their phenocopies ranged widely between labs (18 %–94 % of panel contents). All panels included genes not associated with classic mitochondrial diseases (6 %–28 % of panel contents), including genes causing adult-onset neurodegenerative disorders, cancer predisposition, and other genetic syndromes or inborn errors of metabolism. Five of the panels included genes that are not listed in OMIM to be associated with a disease phenotype (5 %–49 % of panel contents). None of the consent documents reviewed had options for patient preference regarding receipt of incidental findings. These findings raise points of discussion applicable to mitochondrial diagnostics, but also to the larger arenas of exome and genome sequencing, including the need to consider the boundaries between clinical and research testing, the necessity of appropriate informed consent, and the responsibilities of clinical laboratories and clinicians. Based on these findings, we recommend careful evaluation by laboratories of the genes offered on NGS panels, clear communication of the predicted phenotypes, and revised consent forms to allow patients to make choices about receiving incidental findings. We hope that our analysis and recommendations will help to maximize the considerable clinical utility of NGS panels for the diagnosis of mitochondrial disease.

Keywords

Mitochondrial disease diagnosticsClinical gene panelMitochondrial NGS panelInformed consent

Supplementary material

10897_2013_9683_MOESM1_ESM.xlsx (94 kb)
ESM 1(XLSX 94 kb)

Copyright information

© National Society of Genetic Counselors, Inc. 2014

Authors and Affiliations

  1. 1.Department of Pediatrics, Lucile Packard Children’s HospitalStanford UniversityStanfordUSA